Chapter 9: Adrenergic Receptor Antagonists

The discussion on alpha-adrenoceptor antagonists details the pharmacokinetics and mechanisms of nonselective agents like phenoxybenzamine and phentolamine, emphasizing their utility in treating hypertensive episodes associated with pheochromocytoma through noncompetitive and competitive blockade, respectively. The summary further explores selective alpha-1 blockers, such as prazosin, doxazosin, and tamsulosin, highlighting their dual role in managing essential hypertension via vasodilation and relieving urinary obstruction in benign prostatic hyperplasia through smooth muscle relaxation in the prostate and bladder neck. The section on beta-adrenoceptor antagonists, or beta-blockers, provides an in-depth review of their classification into nonselective agents like propranolol and timolol, and cardioselective beta-1 blockers such as atenolol and metoprolol. Key therapeutic mechanisms are explained, including the reduction of heart rate, cardiac contractility, and renin secretion, which substantiate their use in treating hypertension, angina pectoris, cardiac dysrhythmias, and myocardial infarction. The text also covers specific pharmacological properties such as intrinsic sympathomimetic activity found in pindolol, membrane-stabilizing activity, and lipid solubility, which influences central nervous system effects and therapeutic applications like migraine prophylaxis and glaucoma management. Furthermore, the chapter examines third-generation agents like carvedilol and labetalol that antagonize both alpha and beta receptors, with a special focus on carvedilol's antioxidant and cardioprotective neurohumoral effects in heart failure. Finally, the summary addresses potential adverse effects, including bronchoconstriction in asthmatics, masking of hypoglycemia in diabetics, and reflex tachycardia, ensuring a balanced understanding of clinical safety and efficacy.